Amonafide

DB05022InvestigationalSmall molecule

Amonafide is a substance that is being studied in the treatment of cancer. It belongs to the families of drugs called topoisomerase inhibitors and intercalating agents.

Mechanism: Amonafide is a DNA intercalating agent and inhibitor of topoisomerase II that has been extensively studied in patients with malignant solid tumors. Amonafide has also been studied in patients with AML.
Curator reviewed
Primary indication: Investigated for use/treatment in breast cancer, ovarian cancer, and prostate cancer.Curator reviewed
Formula / weight: C₁₆H₁₇N₃O₂ · 283.3251 g/mol (avg)
Code names: NSC-308847

Resolves to

Compound

UNII1Q8D39N37LCAS69408-81-7ChEMBLCHEMBL428676ChEBI94661PubChem50515

Clinical / RWD

RxNorm1440270

Structure

InChIKeyUPALIKSFLSVKIS-UHFFFAOYSA-NSMILESCN(C)CCN1C(=O)C2=CC=CC3=CC(N)=CC(C1=O)=C23

Targets

P11388TOP2AQ02880TOP2B

What you can answer from here — as of July 17, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

39Drug interactionsStructured to mechanism, not free text

4Clinical trialsPhase, status and sponsor resolved per trial

Which drugs share a target with Amonafide, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account